Glucagon-like peptide-1 analogs in the treatment of Type 2 diabetes: a review of the Phase II and III trials

  • Hribal M
  • Sesti G
N/ACitations
Citations of this article
25Readers
Mendeley users who have this article in their library.

Abstract

Glucagon-like peptide-1 (GLP-1) analogs-based therapies are a new option for Type 2 diabetes treatment that hold the promise of overcoming the major limitations of traditional treatments, including the increased risk for hypoglycemia and weight gain. GLP-1 is a naturally occurring hormone that potentiates glucose-dependent insulin secretion. The clinical utility of native GLP-1 is, however, limited by its short half-life; these observations led to the generation of GLP-1 analogs, which mimic GLP-1 action in vivo in humans. Here, we review the data from clinical trials that have assessed mechanism of action, efficacy and safety of GLP-1 agonists; these trials have demonstrated the efficacy of GLP-1 analogs in reducing glycosylated hemoglobin and fasting plasma glucose levels. The use of these drugs was associated with weight loss and reductions in blood pressure, with a low risk of hypoglycemia, GLP-1 agonists were generally well tolerated with the most frequent adverse effects being nausea. © 2011 Future Science Ltd.

Cite

CITATION STYLE

APA

Hribal, M. L., & Sesti, G. (2011). Glucagon-like peptide-1 analogs in the treatment of Type 2 diabetes: a review of the Phase II and III trials. Clinical Investigation, 1(2), 327–343. https://doi.org/10.4155/cli.10.26

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free